Randomized comparison of endothelial progenitor cells capture stent versus cobalt-chromium stent for treatment of ST-elevation myocardial infarction. Six-month clinical, angiographic, and IVUS follow-up

Catheterization and Cardiovascular Interventions

Volumn 76, Issue 5, 2010, Pages 627-631

  Bystroň, Marian ^a   Červinka, Pavel ^a   Špaček, Radim ^a   Kvašňák, Martin ^a   Jakabčin, Jozef ^a   Červinková, Michaela ^a   Kala, Petr ^b   Widimský, Petr ^c  

^a MASARYK UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

endothelial progenitor cells capture stent; primary PCI; ST elevation myocardial infarction; stent thrombosis

Indexed keywords

ANTITHROMBOCYTIC AGENT; CHROMIUM; COBALT; HEPARIN;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY STENT; ENDOTHELIAL PROGENITOR CELLS CAPTURE STENT; FOLLOW UP; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INTERMETHOD COMPARISON; INTRAVASCULAR ULTRASOUND; MALE; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL; SAFETY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS;

AGED; ANGIOPLASTY, BALLOON, CORONARY; CHI-SQUARE DISTRIBUTION; CHROMIUM ALLOYS; CORONARY ANGIOGRAPHY; CZECH REPUBLIC; DRUG THERAPY, COMBINATION; ENDOTHELIAL CELLS; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; RISK ASSESSMENT; RISK FACTORS; STEM CELLS; STENTS; THROMBOSIS; TIME FACTORS; TREATMENT OUTCOME; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 78349262350     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.22612     Document Type: Article

References (18)

1. Andersen HR, Nielsen TT, Vesterlund T, et al. Danish multicenter randomized study on fibrinolytic therapy versus acute coronary angioplasty in acute myocardial infarction: Rationale and design of the Danish trial in acute myocardial infarction-2 (DANAMI-2). Am Heart J 2003; 146: 234-241.
2. Widimsky P, Budesinsky T, Vorac D, et al. Long distance transport for primary angioplasty vs. immediate thrombolysis in acute myocardial infarction. Final results of the randomized national multicentre trial-PRAGUE-2. Eur Heart J 2003; 24: 94-104.
3. Sianos G, Papafaklis MI, Daemen J, et al. Angiographic stent thrombosis after routine use of drug eluing stents in ST-segment myocardial infarction: The importance of thrombus burden. J Am Coll Cardiol 2007; 50: 573-583.
4. Steg PG, Fox KAA, Eagle KA, et al. Mortality following placement of drug-eluting and bare-metal stents for ST-segment elevation acute myocardial infarction in the Global Registry of Acute Coronary Events. Eur Heart J 2009; 30: 321-329.
5. Nakazawa G, Finn AV, Joner M, et al. Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients an autopsy study. Circulation 2008; 118: 1138-1145.
6. Co M, Tay E, Lee CH, et al. Use of endothelial progenitor cell capture stent (Genous Bio-Engineered R Stent) during primary percutaneous coronary intervention in acute myocardial infarction: Intermediate- to long-term clinical follow-up. Am Heart J 2008; 155: 128-132.
7. Kong D, Melo LD, Mangi AA, et al. Enhanced inhibition of neointimal hyperplasia by genetically engineered endothelial progenitor cells. Circulation 2004; 109: 1769-1775.
8. Aoki J, Serruys PW, van Bausekom, et al. Endothelial progenitor cell capture by stents coated with antibody against CD34-The HEALING-FIM (healthy endothelial accelerated lining inhibits neointimal growth-first in man) registry. J Am Coll Cardiol 2005; 45: 1574-1579.
9. Cutlip D,. Impact of stent thrombosis in outcomes of death and MI after drug-eluting stenting. Importance of standard definitions and analytical methods. Available at
10. Duckers HJ, Anuma Y, Benit E, et al. Final results of the HEALING 2B trial to evaluate a bioengineered CD34 antibody coated stent (Genous (TM) Stent) designed to promote vascular healing by capture of circulating endothelial progenitor cells in CAD patients. Am J Cardiol 2008; 102: 187I-188I.
11. Klomp M, Beijk MAM, Verouden NJV, et al. One-year clinical outcome of a real world experience in patients treated with a genous (TM) EPC capturing stent. Am J Cardiol 2008; 102: 183I-183I.
12. Miglionico M, Patti G, D'Ambrosio A, Di Sciascio G,. Percutaneous coronary intervention utilizing a new endothelial progenitor cells antibody-coated stent: A prospective single-center registry in high-risk patients. Cathet Cardiovasc Interv 2008; 71: 600-604.
13. Lee YP, Tay E, Lee ChH, et al. Endothelial progenitor cell capture stent implantation in patients with ST-segment elevation acute myocardial infacrtion: One year follow-up. EuroIntervention 2010; 5: 698-702.
14. Anis A, Normand SLT, Wolf RE, et al. Outcomes following primary percutaneous coronary intervention: A comparison between hospitals with and without cardiac surgery on-site. Circulation 2009; 120: S959.
15. Beijk MAM, Klomp M, Verouden NJW, et al. Genous™ endothelial progenitor cell capturing stent vs. the Taxus Liberté stent in patients with de novo coronary lesions with a high-risk of coronary restenosis: A randomized, single-centre, pilot study. Eur Heart J 2010; 31: 1055-1064.
16. Mauri L, Orav J Kuntz RE,. Late loss in lumen diameter and binary restenosis for drug-eluting stent comparison. Circulation 2005; 111: 3435-3442.
17. Haude M,. CD34 Antibody Covered Stent in STEMI-The Neuss Experience. Meeting of Germany Society of Cardiology, April 2009, Mannheim, Germany.
18. Shintani S, Murohara T, Ikeda H, et al. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation 2001; 103: 2776-2779.